Trial reportBiological psychiatry2013
The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder.
Trial report in Biological psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- TheBrain plasticity (Amsterdam, Netherlands) · 2022Pooled it
- A Case-Control Study and Meta-Analysis Reveal BDNF Val66Met Is a Possible Risk Factor for PTSD.Neural plasticity · 2016Pooled it
- The efficacy and mechanism of an integrated mindfulness-based programme on posttraumatic stress disorder among people with HIV: a randomized controlled trial with 3-month follow up.European journal of psychotraumatology · 2026Trial
- Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer.Translational psychiatry · 2022Trial
- Longitudinal genome-wide methylation study of PTSD treatment using prolonged exposure and hydrocortisone.Translational psychiatry · 2021Trial
- Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome.Brain & development · 2017Trial
- Brain-Derived Neurotropic FactorBioMed research international · 2017Trial
- Exercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy Data.Cognitive behaviour therapy · 2015Trial
- Bounce Back Now! Protocol of a population-based randomized controlled trial to examine the efficacy of a Web-based intervention with disaster-affected families.Contemporary clinical trials · 2015Trial
- Closed-Loop Neuromodulation for Brain Fatigue: From Real-Time Biomarkers to Adaptive Intervention.International journal of molecular sciences · 2026Review
- Association of CREB1 (rs2253206) and BDNF (rs6265) Polymorphisms with Implementation Intentions Treatment Response in Smoking Reduction.Addiction & health · 2025Article
- Interaction of Brain-derived Neurotrophic Factor, Exercise, and Fear Extinction: Implications for Post-traumatic Stress Disorder.Current neuropharmacology · 2024Review
- The forensic aspects of suicide and neurotrophin factors: a research study.Frontiers in pharmacology · 2024Article
- A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder.Focus (American Psychiatric Publishing) · 2023Review
- Reconsolidation and Fear Extinction: An Update.Current topics in behavioral neurosciences · 2023Article
- Psychotherapies and digital interventions for OCD in adults: What do we know, what do we need still to explore?Comprehensive psychiatry · 2023Review
- Is Fear Extinction Impairment Central to Psychopathology?Current topics in behavioral neurosciences · 2023Article
- Suicide and Neurotrophin Factors: A Systematic Review of the Correlation between BDNF and GDNF and Self-Killing.Healthcare (Basel, Switzerland) · 2022Review
- Review
- Infralimbic BDNF signaling is necessary for the beneficial effects of extinction on set shifting in stressed rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe most effective treatment for posttraumatic stress disorder (PTSD) is exposure therapy, which aims to facilitate extinction of conditioned fear. Recent evidence suggests that brain-derived neurotrophic factor (BDNF) facilitates extinction learning. This study assessed whether the Met-66 allele of BDNF, which results in lower activity-dependent secretion, predicts poor response to exposure therapy in PTSD.
methodsFifty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva to extract genomic DNA to determine their BDNF Val66Met genotype (30 patients with the Val/Val BDNF allele, 25 patients with the Met-66 allele). We examined whether BDNF genotype predicted reduction in PTSD severity following exposure therapy.
resultsAnalyses revealed poorer response to exposure therapy in the PTSD patients with the Met-66 allele of BDNF compared with patients with the Val/Val allele. Pretreatment Clinician Administered PTSD Scale severity and BDNF Val66Met polymorphism predicted response to exposure therapy using hierarchical regression.
conclusionsThis study provides the first evidence that the BDNF Val66Met genotype predicts response to cognitive behavior therapy in PTSD and is in accord with evidence that BDNF facilitates extinction learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.